Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics (Nasdaq: TRVI) announced management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 9:20 a.m. ET.
Jennifer Good, President and CEO, and David Hastings, CFO, will speak and hold investor meetings during the virtual conference Feb 25–26. Trevi is a clinical-stage biopharmaceutical developing Haduvio (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough.
Trevi Therapeutics (Nasdaq: TRVI) announced that key Phase 2b CORAL trial results for oral nalbuphine ER in idiopathic pulmonary fibrosis (IPF) chronic cough were published in JAMA on Jan 22, 2026. The trial showed a statistically significant reduction in 24-hour objective cough frequency across all dose groups at Week 6, with significant effects as early as Week 2. More than 60% of treated patients achieved ≥50% reduction in 24-hour cough frequency at Week 6. Patient-reported outcomes aligned with objective monitoring. Safety was consistent with prior data; discontinuations due to adverse events were 6% in treated groups versus 5% for placebo.
Getty Realty (NYSE: GTY) announced the 2025 dividend tax allocations for its common stock (CUSIP 374297109) as they will appear on Form 1099-DIV.
The company reported total 2025 distributions of $1.880000 per share, comprised of ordinary income $1.085936, capital gains $0.050080 (including unrecaptured Sec 1250 of $0.009692) and non-dividend distributions $0.743984. Dividends were paid quarterly with record dates 12/26/2024, 3/27/2025, 6/26/2025 and 9/25/2025 and payable dates 1/9/2025, 4/10/2025, 7/10/2025 and 10/9/2025.
A tax disclaimer advised shareholders to consult their tax advisors for specific federal, state and local tax consequences. As of 12/31/2025, Getty reported a portfolio of 1,174 properties in 44 states and Washington, D.C.
Trevi Therapeutics (Nasdaq: TRVI) provided strategic clinical updates ahead of the LifeSci Partners event (Jan 12-14, 2026) during J.P. Morgan week. The company has an FDA End-of-Phase 2 meeting scheduled in Q1 2026 for nalbuphine ER (Haduvio) for chronic cough in IPF and expects to initiate a Phase 3 program in IPF in H1 2026 following that meeting. Trevi also plans to start a Phase 2b trial in refractory chronic cough (RCC) in H1 2026. New CFO David Hastings will attend the LifeSci event with senior management.
Trevi Therapeutics (Nasdaq: TRVI) announced that David Hastings will become Chief Financial Officer effective January 6, 2026.
Mr. Hastings brings over 25 years of life‑science financial leadership, having raised more than $2B in equity and debt and held CFO roles at Arbutus, Unilife, Incyte, and ArQule. He served as CFO during Incyte's commercialization of Jakafi and co‑led out‑licensing negotiations; he currently chairs the audit committee at Scynexis.
Management says Hastings will help guide Trevi as it advances Haduvio (oral nalbuphine ER) into Phase 3 development for chronic cough in IPF, non‑IPF ILD, and RCC, citing statistically significant data, limited competition, and a strong cash position.
Trevi Therapeutics (Nasdaq: TRVI) reported third-quarter 2025 results and clinical updates on November 13, 2025. The company ended Q3 2025 with $194.9 million in cash, cash equivalents and marketable securities and expects a cash runway into 2028. Trevi plans to request an End-of-Phase 2 meeting with the FDA in Q4 2025 and to initiate a Phase 3 IPF chronic cough program in H1 2026. A Phase 1 IPF safety study (TIDAL) sentinel cohort showed no safety signals; enrollment completion and study data are expected in Q4 2025. A Phase 1 drug-drug interaction study showed no clinically meaningful PK interactions with pirfenidone or nintedanib. Topline Phase 2b CORAL and Phase 2a RIVER results were presented at CHEST 2025 and ERS Congress 2025. Q3 2025 net loss was $11.8 million.
Trevi Therapeutics (Nasdaq: TRVI) announced a conference call and live audio webcast for Thursday, November 13, 2025 at 4:30 p.m. ET to provide a corporate update and review third quarter financial results for the period ended September 30, 2025.
Senior management will host the call; domestic dial-in is (877) 870 4263 and international dial-in is (412) 317 0790. No access code is required. A live audio webcast will be available from the Investors & News section at www.TreviTherapeutics.com, with an archived replay accessible on the company website for 30 days after the event.
Trevi Therapeutics (Nasdaq: TRVI) announced management will participate in the Stifel 2025 Healthcare Conference in New York on November 11–12, 2025.
A fireside chat featuring Jennifer Good, President and CEO, and James Cassella, Ph.D., Chief Development Officer, is scheduled for Tuesday, November 11, 2025 at 3:20 p.m. ET. Company executives will also hold investor meetings with conference attendees. The fireside chat and meetings will be available for in-person attendees.
Trevi Therapeutics (Nasdaq: TRVI) announced two accepted abstracts for presentation at the CHEST 2025 Annual Meeting in Chicago, Oct 19–22, 2025. Key efficacy and safety results from the Phase 2b CORAL dose‑ranging trial of oral nalbuphine ER in patients with idiopathic pulmonary fibrosis (IPF) will be presented orally by Philip Molyneaux on Oct 21, 1:45–2:30pm CDT. Patient‑reported outcomes from the Phase 2a RIVER proof‑of‑concept trial in refractory chronic cough (RCC) will be presented as a poster by Imran Satia on Oct 21, 1:45–2:30pm CDT. Both items appear in late‑breaking scientific abstract sessions and target clinicians and researchers focused on chronic cough and interstitial lung disease.
Trevi Therapeutics (Nasdaq: TRVI) announced that data from its Phase 2a RIVER trial of Haduvio™ (oral nalbuphine ER) will be presented in two poster sessions at the European Respiratory Society (ERS) Congress 2025 in Amsterdam. The presentations will focus on the efficacy, safety, and responder analysis of nalbuphine ER in treating refractory chronic cough (RCC).
The posters will be presented on September 28-29, 2025, covering results from the trial investigating Haduvio™ for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and RCC.